Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Earnings Per Share, Basic and Diluted

The calculation of basic and diluted earnings per common share is as follows (in thousands, except per share amounts):


	Year Ended December 31,
	2023		2022		2021
Numerator:
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders, basic	$	(892,869)	$	(2,104,929)	$	(1,830,047)
Less: change in fair value of warrant liabilities	—		—		58,615
Less: change in fair value of contingent consideration common shares liability	—		3,143		—
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders, diluted	$	(892,869)	$	(2,108,072)	$	(1,888,662)
Denominator
Weighted average common shares outstanding, basic	1,944,420		1,679,061		1,359,849
Effect of dilutive securities:
Warrants	—		—		525
Contingent consideration common shares	—		777		—
Weighted average common shares outstanding, diluted	1,944,420		1,679,839		1,360,373
Basic net loss per share	$	(0.46)	$	(1.25)	$	(1.35)
Diluted net loss per share	$	(0.46)	$	(1.25)	$	(1.39)

Summary of Anti-Dilutive Shares

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive (in thousands):


	As of December 31,
	2023	2022	2021
Unvested RSUs	152,168	134,436	168,322
Ginkgo and Sponsor earnout shares (1)	152,122	156,781	160,995
Warrants to purchase Class A common stock	51,825	51,825	—
Outstanding stock options	7,688	12,711	25,229
Unvested RSAs	—	4	183
	363,803	355,757	354,729

(1)Represents earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied.